U.S. Infectious Respiratory Disease Diagnostics Market Size, Share & Trends Analysis Report by Product, Technology, Application, End-Use, and Growth Forecasts, 2026-2033

The U.S. infectious respiratory disease diagnostics market size was estimated at USD 4.50 billion in 2025 and is projected to reach USD 5.70 billion by 2033, growing at a CAGR of 2.98% from 2026 to 2033, driven by the sustained and recurring burden of viral and bacterial respiratory infections including influenza, respiratory syncytial virus (RSV), COVID-19, tuberculosis, and other emerging respiratory pathogens. Seasonal outbreaks, periodic waves of respiratory infections, and increasing urbanization have strengthened the demand for early, accurate, and scalable diagnostic solutions across hospitals, public health laboratories, and decentralized care settings throughout the U.S.

The industry is driven by the high and persistent burden of respiratory infections, which continues to generate strong demand for accurate and rapid diagnostic solutions. Diseases such as influenza, RSV, tuberculosis, and bacterial pneumonia contribute significantly to healthcare utilization across the country. For instance, RSV alone leads to approximately 177,000 hospitalizations and 14,000 deaths annually among adults aged 65 years and older in the U.S., while the CDC estimated around 40 million influenza cases and over 470,000 hospitalizations during the 2023-2024 season. This sustained disease prevalence reinforces the need for reliable diagnostics across hospitals, outpatient settings, and public health surveillance programs.

Technological advancements are significantly reshaping the market landscape, with a clear transition toward multiplex molecular diagnostics and automated platforms. Modern diagnostic systems now enable simultaneous detection of multiple pathogens such as SARS-CoV-2, influenza A/B, and RSV from a single sample, improving clinical decision-making and reducing turnaround times. For example, Roche’s cobas Respiratory 4-flex test, which received FDA 510(k) clearance in August 2025, can identify four major respiratory viruses in one run, while the upgraded cobas 6800/8800 systems launched in December 2025 enhance laboratory productivity and efficiency. These innovations, along with automation and sequencing technologies, are enabling laboratories to handle higher testing volumes and improve diagnostic accuracy.

Rising investments in research and development are further accelerating market growth by supporting innovation in diagnostic platforms and expanding testing capabilities. Government agencies, nonprofit organizations, and private companies are increasingly funding initiatives to improve early detection and disease monitoring. In October 2025, the American Lung Association invested USD 22 million in research grants supporting over 130 scientists working on respiratory diseases, including diagnostic advancements. Additionally, public-private partnerships and pharmaceutical collaborations are fostering the development of companion diagnostics for RSV, influenza, and COVID-19, enhancing both clinical trials and post-market surveillance.

Furthermore, increasing government support and funding for infectious disease control programs, particularly for tuberculosis, is strengthening diagnostic infrastructure and expanding access to testing. The U.S. government allocates over USD 400 million annually toward TB programs through organizations such as U.S.AID and the Global Fund, promoting better detection and management. Combined with the growing focus on antimicrobial resistance and rapid pathogen identification highlighted by innovations such as NG Biotech’s rapid assays for drug-resistant infections receiving FDA Breakthrough Device Designation in February 2026, the market is expected to witness sustained growth, supported by continuous technological evolution and strong institutional backing.

U.S. Infectious Respiratory Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. infectious respiratory disease diagnostics market report on the basis of product, technology, end-use, and region:

Product Outlook (Revenue, USD Million, 2021-2033)

• Instruments
• Reagents
• Services

Technology Outlook (Revenue, USD Million, 2021-2033)

• Molecular Diagnostics
• Immunoassays
• Microbiology
• Rapid/Point-of-Care Diagnostics
• Other Technologies

Application Outlook (Revenue, USD Million, 2021-2033)

• COVID-19
• Influenza
• Tuberculosis
• Respiratory Syncytial Virus (RSV)
• Non-tuberculosis Mycobacterium Testing
• Bacterial Pneumonia Testing
• Other Respiratory Diseases

End-use Outlook (Revenue, USD Million, 2021-2033)

• Hospitals
• Clinics
• Diagnostics Laboratories
• Research Institutes

Why should you buy this report?

• Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
• Competitive Landscape: Explore the market presence of key players.
• Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
• Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

• Market intelligence to enable effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listings for you to stay ahead of the curve